How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00981227 Recruitment Status : Completed First Posted : September 22, 2009 Results First Posted : May 3

2009 Clinical Trials

202. Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00980746 Recruitment Status : Completed First Posted : September 21, 2009 Results First Posted

2009 Clinical Trials

203. Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2009 Clinical Trials

204. Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00900237 Recruitment Status : Completed First Posted : May 12

2009 Clinical Trials

205. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00957684 Recruitment Status : Completed First Posted : August 12, 2009 Results First Posted : October 10

2009 Clinical Trials

206. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00957372 Recruitment Status : Completed First Posted : August 12, 2009 Results First Posted : August 5

2009 Clinical Trials

207. Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Results First Posted : August 5, 2013 Last Update Posted : July 2, 2014 Sponsor: Bial - Portela C S.A. Information provided by (Responsible Party): Bial - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who (...) complete Part I may enter a 1-year open-label extension. Condition or disease Intervention/treatment Phase Partial Epilepsy Drug: eslicarbazepine acetate Drug: placebo Drug: ESL - Part II Phase 3 Detailed Description: Part I was a 22-week parallel-group, randomized, placebo-controlled period (8 weeks baseline, 2 weeks double-blind titration, and 12 weeks maintenance). After completing the baseline period, patients were randomized in a 1:1:1:1 ratio to 1 of the 3 ESL dose levels or to placebo. Part II

2009 Clinical Trials

208. Eslicarbazepine Acetate Monotherapy Long Term Study

Eslicarbazepine Acetate Monotherapy Long Term Study Eslicarbazepine Acetate Monotherapy Long Term Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Eslicarbazepine Acetate Monotherapy Long Term Study (...) Summary: This is a long term, open-label, safety extension study in subjects with partial onset seizures. Condition or disease Intervention/treatment Phase Epilepsy Drug: Eslicarbazepine acetate Phase 3 Detailed Description: This is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option

2009 Clinical Trials

209. Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00898560 Recruitment Status : Completed First Posted : May 12

2009 Clinical Trials

210. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. (Abstract)

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures.Double-blind, placebo-controlled, parallel-group, multicenter study consisting of an 8-week baseline period, after which patients were randomized to placebo (n = 87) or once-daily ESL 800 mg (n = 85) or 1200 mg (n = 80). Patients

2009 Acta neurologica Scandinavica Controlled trial quality: uncertain

211. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. (Abstract)

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults with >or=4 partial-onset seizures (simple or complex, with or without secondary generalization) per 4 weeks despite treatment with 1-2 antiepileptic drugs (AEDs

2009 Epilepsia Controlled trial quality: predicted high

212. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. (Abstract)

Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Eslicarbazepine acetate (ESL) is a new voltage-gated sodium channel blocker currently in development for the treatment of neuropathic pain, including that of diabetic origin. The primary objective was to investigate the effect of ESL on the pharmacokinetics of metformin, a commonly used oral antidiabetic drug.Randomized, open-label, two-way crossover study in 20 healthy subjects. The volunteers received

2009 International journal of clinical pharmacology and therapeutics Controlled trial quality: uncertain

213. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. (Abstract)

Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Eslicarbazepine acetate (ESL) is a new-generation voltage-gated sodium channel blocker, which has been demonstrated to be effective and well tolerated in the treatment of epilepsy. The primary objective of this study was to investigate the effect of ESL on the pharmacokinetics of digoxin. This study was a randomized, double-blind, placebo-controlled, two-way crossover study of 12 healthy subjects (six men

2009 Fundamental & clinical pharmacology Controlled trial quality: predicted high

214. Therapeutic Drug Monitoring

. There are several categories of drugs that require monitoring, as summarised here. Drug Category Drugs Treatment Use Cardiac drugs , digitoxin, amiodarone , , Antibiotics Aminoglycosides (gentamicin, tobramycin, amikacin, , chloramphenicol) Infections with bacteria that are resistant to less powerful antibiotics Antiepileptics , , , , (rarely: ethosuximide, gabapentin, lamotrigine, levetiracetam, topiramate, zonisamide, eslicarbazepine, felbamate, lacosamide, oxcarbazepine, pregabalin, rufinamide, stiripentol

2004 Lab Tests Online UK

215. Pill Questions - What to Ask When Starting the OCP.

with special needs. For information on guidelines surrounding prescribing for girls under the age of 16, see the separate article. Interactions [ , , ] There are many commonly used medications which can affect the efficacy of the pill: Antibacterials - enzyme inducers only - eg, rifampicin, rifabutin. Antidepressants - St John's wort (which can be bought over-the-counter). Anticonvulsants - carbamazepine, oxcarbazepine, eslicarbazepine, phenobarbital, phenytoin, primidone and topiramate due to their enzyme

2008 Mentor

216. Temporal Lobe Epilepsy

valproate should be considered if carbamazepine and lamotrigine are unsuitable or not tolerated. Adjunctive treatment: offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated. Other anti-epileptic drugs (AEDs) that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine

2008 Mentor

217. Anticonvulsants used for Partial Seizures

, levetiracetam, oxcarbazepine, sodium valproate, perampanel or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated. Other AEDs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. NB : carefully consider the risk:benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. Interactions [ ] Interactions

2008 Mentor

218. Contraception and Special Groups

: rifampicin and rifabutin. Anti-epileptics: carbamazepine, eslicarbazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate. Central nervous system stimulant: modafinil. Antiretroviral drugs: nelfinavir, nevirapine, ritonavir. St John's wort. Combined hormonal contraception COC pill - all women should be advised to switch to a contraceptive method unaffected by enzyme inducers (eg, progestogen-only injectable, copper intrauterine device (Cu-IUCD) or LNG-IUS). Rifampicin and rifabutin

2008 Mentor

219. Combined Oral Contraceptive (Follow-up and Common Problems)

to show any evidence that significant weight gain is a side-effect of the pill. [ ] Interactions [ , , ] There are many commonly used medications which can affect the efficacy of the pill: Antibacterials - enzyme inducers only (eg, rifampicin, rifabutin). Antidepressants - St John's wort (which can be bought over-the-counter). Anticonvulsants - carbamazepine, oxcarbazepine, eslicarbazepine, phenobarbital, phenytoin, primidone and topiramate, due to their enzyme-inducing activity. Also lamotrigine

2008 Mentor

220. Anticonvulsants used for Generalised Seizures

are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Idiopathic generalised epilepsy (IGE) First-line treatment: offer sodium valproate as first-line treatment, particularly if there is a photo-paroxysmal response on EEG. Offer lamotrigine if sodium valproate is unsuitable or not tolerated. Lamotrigine can exacerbate myoclonic seizures. Consider topiramate but it has a less favourable side-effect profile than sodium valproate and lamotrigine

2008 Mentor

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>